JMCC Group has agreed to participate as one of five medical cannabis providers worldwide for Project Twenty21, as the exclusive Caribbean supplier of cannabis-based medicines to patients across the United Kingdom taking part in the ground-breaking study.
Drug Science, the UK’s only independent drugs research charity, launched Project Twenty21, Europe’s first and biggest national medical cannabis registry, in November 2019. The project involves enrolling up to 20,000 patients by the end of 2021 in the study, to create the largest body of evidence for the effectiveness and tolerability of medical cannabis.
The key objectives of Project Twenty21 are to create the largest body of evidence in Europe for the effectiveness and tolerability of medical cannabis, and to demonstrate to policymakers that medical cannabis should be as widely available, and affordable, as other approved medicines, for patients who would benefit from them. The project will also help prescribers across the country to gain knowledge and confidence in prescribing medical cannabis for patients. Drug Science hopes that the findings will make a powerful case for National Health Service (NHS) funding of cannabis-based treatments, by proving the favourable risk/benefit ratio for seven key identified conditions, specifically focusing on patients for whom alternative treatments have failed. The targeted conditions are Anxiety Disorder, Chronic Pain, Epilepsy, Multiple Sclerosis (MS), Post-Traumatic Stress Disorder (PTSD), Substance Use Disorder (as a harm reduction strategy), and Tourette’s Syndrome.
Treatment will be provided by a network of clinics and private prescribers across the UK, which utilize best practices developed by experienced medical cannabis specialists. The medical cannabis prescribed will be provided, at cost, by recognized global leaders in medical cannabis, and will now include JMCC.
JMCC was specifically invited to support Project Twenty21.
“We were so impressed when we met Diane Scott last year,” said Drug Science Founder Professor David Nutt, referring to JMCC Group’s Chair & CEO). “She has a unique appreciation for where the medical cannabis industry should be going. And she was singularly determined that JMCC would keep to that direction, where the company would continue to, first and foremost, serve patients. So JMCC was a natural partner for us in Project Twenty21.”
“When I first heard about this project, I immediately thought how bold and visionary it was,” Diane Scott said. “We were already planning JMCC’s evolution as a company, from being the best grower of Jamaican medical cannabis to developing our own world-class cannabis-based medical products. So, when David invited me to discuss it, and told me more about Project Twenty21, and asked us to participate, how could we not be honoured to help patients in the UK this way?”
“The whole company is behind it. And, as a dual Canadian-UK citizen, I’m personally delighted that we’re taking part,” Ms. Scott added.
Five months after that first meeting, JMCC is announcing both its participation in Project Twenty21 and the launch of a new divisions, JMCC Scientific, which will support both that participation and JMCC’s future expansion.
For more information:
JMCC
David Badcock
CEO, Drug Science
T: +44 07501 919193
E: david.badcock@drugscience.org.uk
Shelley Boyes
Global Marketing & Communications Director, JMCC
T: +1 416.272.8981
E: shelley.boyes@jamaicanmedicann.com
Andrea Chrysanthou
Global Public Affairs
T: +1 416.797-8194
E: achrysanthou@globalpublic.com